← Leaderboards
Juliane Bubeck Wardenburg
Washington University
$13,099,316
Attributed
$15,652,066
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2009–25$2.5M$1.9M$1.3M$625K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,652,066 · 11
By mechanism
R01$9,094,418 · 3
U54$2,387,932 · 1
T32$1,934,960 · 1
R21$1,934,756 · 5
R41$300,000 · 1
Top collaborators
- Stephanie Ann Fritz5 shared
- Kory J. Lavine3 shared
- Robert P. Mecham2 shared
Most similar at Washington University
Same institution · by research overlap
- Christopher Daniel Smyser$22,079,913
- Joan L Luby$32,934,481
- Ingrid Bernadette Borecki$9,809,084
- Stephanie Ann Fritz$8,750,405
- Danielle Nicole Alfano$390,314
Others in their field
Top investigators on “Pathogenesis”
- Jeffrey P Krischer · University Of South Florida$473,867,135
- Constance Ann Benson · University Of California, San Diego$309,631,408
- Daniel R Kuritzkes · Brigham And Women'S Hospital$212,627,101
- Richard K. Wilson · Washington University$203,917,615
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$198,007,440
- Carol Nesel · Westat$147,274,423
Research focus
PathogenesisLifeMediatingToxinCellsInfectionBaseMolecularComplexImmunityAntimicrobial ResistanceMorbidity - Disease RateOrganismStaphylococcus AureusCessation Of LifePneumoniaPreventSepsisVaccinesChildTissuesInvestigationCoupledPredisposition
Grant awards (40)
Development of human adaptive immunity to Staphylococcus aureus$640,665
R01 · FY2025 · AI · contact PI
Modulation of neutrophil-endothelial interactions by ADAM10$226,253
R21 · FY2025 · AI · contact PI
Novel Bacteroides fragilis Competition Factor in Carbapenem-Resistant Strains$194,375
R21 · FY2025 · AI · contact PI
Development of human adaptive immunity to Staphylococcus aureus$628,474
R01 · FY2024 · AI · contact PI
Pediatric Cardiovascular and Pulmonary Research Training Program$297,425
T32 · FY2024 · HL · contact PI
Novel Bacteroides fragilis Competition Factor in Carbapenem-Resistant Strains$233,250
R21 · FY2024 · AI · contact PI
ADAM10 polymorphism in susceptibility to S. aureus disease$194,375
R21 · FY2024 · AI · contact PI
Development of human adaptive immunity to Staphylococcus aureus$628,474
R01 · FY2023 · AI · contact PI
Pediatric Cardiovascular and Pulmonary Research Training Program$352,874
T32 · FY2023 · HL · contact PI
ADAM10 polymorphism in susceptibility to S. aureus disease$234,003
R21 · FY2023 · AI · contact PI
Development of human adaptive immunity to Staphylococcus aureus$628,474
R01 · FY2022 · AI · contact PI
Pediatric Cardiovascular and Pulmonary Research Training Program$442,922
T32 · FY2022 · HL · contact PI
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility$393,750
R01 · FY2022 · AI · contact PI
Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection$300,000
R41 · FY2022 · AI · contact PI
Enterotoxigenic Bacteroides fragilis in modulation of host immunity$236,250
R21 · FY2022 · AI · contact PI
Development of human adaptive immunity to Staphylococcus aureus$644,454
R01 · FY2021 · AI · contact PI
Pediatric Cardiovascular and Pulmonary Research Training Program$426,669
T32 · FY2021 · HL · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$395,039
R01 · FY2021 · AI · contact PI
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility$393,750
R01 · FY2021 · AI · contact PI
Enterotoxigenic Bacteroides fragilis in modulation of host immunity$196,875
R21 · FY2021 · AI · contact PI
Pediatric Cardiovascular and Pulmonary Research Training Program$415,070
T32 · FY2020 · HL · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$401,218
R01 · FY2020 · AI · contact PI
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility$393,750
R01 · FY2020 · AI · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$407,340
R01 · FY2019 · AI · contact PI
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility$392,709
R01 · FY2019 · AI · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$412,696
R01 · FY2018 · AI · contact PI
Enterotoxigenic B. fragilis Acquisition in Disease Susceptibility$389,375
R01 · FY2018 · AI · contact PI
Analysis of ADAM10 in infection-associated MODS$190,625
R21 · FY2018 · HD · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$417,650
R01 · FY2017 · AI · contact PI
Analysis of ADAM10 in infection-associated MODS$228,750
R21 · FY2017 · HD · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$390,000
R01 · FY2016 · AI · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$390,000
R01 · FY2015 · AI · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$390,000
R01 · FY2014 · AI · contact PI
Staphylococcus aueaus vaccine development$482,089
U54 · FY2013 · AI · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$366,600
R01 · FY2013 · AI · contact PI
Staphylococcus aueaus vaccine development$489,334
U54 · FY2012 · AI · contact PI
Role of Staphylococcus aureus alpha-hemolysin in disease$390,000
R01 · FY2012 · AI · contact PI
Staphylococcus aueaus vaccine development$499,463
U54 · FY2011 · AI · contact PI
Staphylococcus aueaus vaccine development$471,281
U54 · FY2010 · AI · contact PI
Staphylococcus aueaus vaccine development$445,765
U54 · FY2009 · AI · contact PI